

To
the Honourable
Mr El. Papageorgopoulos
President of EOPPY

Cc.: Mrs P. Litsa, Director of the Directorate of Medicines of EOPPY
Mrs F. Perdiki, Head of the Directorate of Financial Services and & Conclusion
of Contracts

Chalandri, February 19, 2013

Dear Mr Papageorgopoulos,

Further to our meeting today, we re-address the critical issue of the settlement of EOPPY's-IKA's outstanding debts towards pharmaceutical enterprises, which have now reached the excessive amount of Euro 800 million.

It is rather surprising that selective settlement of invoices is often effected, with non-transparent criteria, leading to discriminating treatment among the healthcare providers at the expense of pharmaceutical enterprises, particularly when those enterprises, in contrast to all other suppliers in the industry, have had zero receipts from EOPPY-IKA in the past two years.

Such practices can in no case be accepted, given that they lead to distortions and lack of transparency.

In order for pharmaceutical enterprises to survive and in order to ensure access of Greek patients to medicines, which is necessary now, more than ever, we would like to forward you in writing the request and the necessity for the **immediate settlement of EOPPY's debts, at least those accumulated in the first six-months of 2012.**

For all the above reasons, we kindly request that you personally undertake the said matter, in order to secure a procedure for transparent and immediate settlement.

Awaiting for your positive response.

Yours sincerely,

Konstantinos M. Frouzis
President

Fotis Mangalousis
General Manager